CLINICAL_TRIALS
trial_result
· 2019-12-04
Clinical Trial Update: A Phase 2 Study of BGJ398 in Patients With Recurrent GBM [Phase 2]
Summary
A Phase 2 study of BGJ398 in patients with recurrent glioblastoma and related glioma subtypes has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Recurrent Glioblastoma or Other Glioma Subtypes | Phase 2 | Status: COMPLETED | Results posted: 2019-12-04